Combidex References

Quick Search


  1. Hovels AM, Heesakkers RA, Adang EM et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clinical Radiology 2008;63:387.
  2. Heesakkers RAM, Jager GJ, Hovels AM et al. Prostate Cancer: Detection of Lymph Node Metastases Outside the Routine Surgical Area with Ferumoxtran-10-enhanced MR Imaging. Radiology 2009; 251:408.
  3. Meijer HJM, Fortuiin AS, van Lin ENJTh et al. Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients. Radiot Oncol 2013;106:59-63.
  4. Meijer HJM, van Lin ENJTh, Debats OA, et al. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. IJORB 2012;82:1405-1410.
  5. Meijer HJM, Debats OA, van Lin ENJTh, Witjes JA, et al. A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured. Radiation Oncology 2013; 8:190.
  6. Meijer HJ, Debats OA, Kunze-Busch M, et al. Magnetic resonance lymphography-guided selective high-dose lymph node irradiation in prostate cancer. IJROB 2012;82:175-183.
  7. Weidner AM, van Lin ENJTh, Dinter DJ, et al 2011 et al. Ferumoxtran-10 MR Lymphography for Target Definition and Follow-up in a Patient Undergoing Image-Guided, Dose-Escalated Radiotherapy of Lymph Nodes upon PSA Relapse Strahelentherapie und Oncol. 2011:206-212.
  8. Harisinghani MG, Barentsz JO, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. NEJM 2003;348:2491-2499.
  9. Wu L, Cao Y, Liao C, Huang J, Gao F. Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: A meta-analysis. EJR 2011;80:582-589.
  10. Heesakkers RA, Hovels AM, Jager GJ et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncology 2008.
  11. Fortuin AS, Smeek RJ, Meijer HJM, Witjes JA, Barentsz JO. Lymphotropic Nanoparticle-enhanced MRI in Prostate Cancer: Value and Therapeutic Potential. Cur Urol Rep 2014;15:389.
  12. Fortuin AS, Meijer HJM, Thompson LC, Witjes JA, Barentsz JO. Ferumoxtran-10 Ultrasmall Superparamagnetic Iron Oxide–Enhanced Diffusion-weighted Imaging Magnetic Resonance Imaging for Detection of Metastases in Normal-sized Lymph Nodes in Patients with Bladder and Prostate Cancer: Do We Enter the Era After Extended Pelvic Lymph Node Dissection? Eur Urol 2014
  13. Birkhauser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall superparamagnetic particles of iron oxide–enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol. 2014
  14. Fortuin AS, Deserno WMLLG, Meijer HM, et al. al. Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients With Lymph Node Metastases. IJROB 2012;84:712-718.
  15. Hovels AM, Heesakkers RAM, Adang EM, Jager GJ, Barentsz JO. Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT. Eur Radiol 2004; 14:1707.
  16. Hovels AM, Heesakkers RA, Adang EM et al. Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer. Radiology 2009;252:729-736.
  17. Deserno WM, Debats OA, Rozema T et al. Comparison of nodal risk formula and MR lymphography for predicting lymph node involvement in prostate cancer. IJROB 2011;81:8-15.
  18. Meijer, HJ, Debats OA, Roach M 3rd, et al. Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram. IJROB 2012;84:1186-1191.
  19. Meijer HJ, Debats OA, van Lin ENJTh et al. Individualized image-based lymph node irradiation for prostate cancer. Nat Rev Urol 2013;10:376-385.

Related Posts: